Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
Top Cited Papers
- 1 January 2010
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 11 (1), 21-28
- https://doi.org/10.1016/s1470-2045(09)70311-0
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patientsRadiotherapy and Oncology, 2009
- Cetuximab for the Treatment of Colorectal CancerNew England Journal of Medicine, 2007
- Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and FluoropyrimidinesJournal of Clinical Oncology, 2006
- Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysisThe Lancet, 2006
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell, 2005
- An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck CancerJournal of Clinical Oncology, 2003
- Forest plots: trying to see the wood and the treesBMJ, 2001
- Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and RadiationCancer Biotherapy & Radiopharmaceuticals, 1999
- Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal CancerNew England Journal of Medicine, 1991
- Pre‐operative irradiation in the treatment of advanced laryngeal carcinomaThe Laryngoscope, 1971